Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0115
COMMENTARY
|
Laparoscopic D2 gastrectomy: A new horizon even in the West
|
Prof. Dr.med. Ernst Hanisch, M.D.
|
Affiliation: Prof. Dr.med. Ernst Hanisch, Chefarzt und Ärztlicher Direktor, Klinik für Allgemein- Viszeral- und Endokrine Chirurgie, Asklepios Klinik Langen, Akademisches Lehrkrankenhaus der JWG-Universität Frankfurt, Röntgenstr 20, 63225 Langen .
Tel 06103/912 61200; FAX 06103/9121814,
Email: E.Hanisch@Asklepios.com |
ABSTRACT
Since there is no abstract available we provide the first paragraph .
Open gastrectomy with extended (D2) lymphadenectomy for the treatment of resectable gastric cancer has become the de facto standard of care in Japan and Korea . Excellent outcomes for advanced stages of this disease have reported recently from a high-quality, multicenter, phase III, randomized, controlled trial at 24 hospitals in Japan [1]. Sasako et al. reported a 5-year survival rate of 70% with extended lymphadenectomy for Japanese stages II and III disease without adjuvant treatment [1]. Yet, these results represent a dream for the real western world [2]. Even in specialized institutions in the west, 5-year survival rate for these advanced stages is reported to be less than 40%, and notably these data are derived from nonrandomized studies [3].
http://www.gastricbreastcancer.com/grade_daytona.asp
http://www.gastricbreastcancer.com/grade_aquaterra.asp
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
